Arrowhead Research Corporation (ARWR) Shares are Down -0.5%

Arrowhead Research Corporation (ARWR) has risen sharply, recording gains of 2.58% in the past 4 weeks. However, the stock has corrected -0.5% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.53% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 2.01% and the 50-Day Moving Average is 3.24%. Arrowhead Research Corporation (NASDAQ:ARWR): stock turned positive on Friday. Though the stock opened at $5.72, the bulls momentum made the stock top out at $6.03 level for the day. The stock recorded a low of $5.6801 and closed the trading day at $5.96, in the green by 3.83%. The total traded volume for the day was 553,721. The stock had closed at $5.74 in the previous days trading.


The company Insiders own 3.9% of Arrowhead Research Corporation shares according to the proxy statements. Institutional Investors own 34.05% of Arrowhead Research Corporation shares. Also, Chardan Capital initiates coverage on Arrowhead Research Corporation (NASDAQ:ARWR). The shares have now been rated Buy by the stock experts at the ratings house. Chardan Capital announces the current price target of $12 per share on Arrowhead Research Corporation. The rating by the firm was issued on May 19, 2016.

Arrowhead Research Corporation develops drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, the Companys therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Companys drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Its second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.